4-甲氧基-2,3-二甲基苯磺酰氯 | 90416-51-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲氧基-2,3-二甲基苯磺酰氯
• 英文名称: 4-methoxy-2,3-dimethylbenzenesulfonyl chloride
• 英文别名: 4-Methoxy-2,3-dimethyl-benzol-sulfonyl-(1)-chlorid
• CAS: 90416-51-6
• 化学式: C₉H₁₁ClO₃S
• mdl: MFCD11133877
• 分子量: 234.704
• InChiKey: WYOJSJPQGYIIIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  4-甲氧基-2,3-二甲基苯磺酰氯 、 methyl 4-((2-aminophenyl)ethynyl)benzoate 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  5-{2-[5-氯-2-(5-乙氧基喹啉-8-磺酰胺基)苯基]乙炔基}-4-甲氧基吡啶-2-羧酸的发现，一种用于解剖MCT4生物学的高选择性体内可用化学探针

  摘要：

  由于葡萄糖代谢过程中乳酸产生增加，肿瘤细胞严重依赖有效的乳酸转运来避免细胞内乳酸积累和酸化。单羧酸转运蛋白 4 (MCT4/SLC16A3) 是一种乳酸转运蛋白，在肿瘤 pH 调节中发挥核心作用。描述了通过 MDA-MB-231 细胞筛选鉴定的一类新型 MCT4 抑制剂（命中9a ）的发现和优化。在溶解 GFP 标记的转运蛋白后，通过荧光互相关光谱和显微镜研究显示了优化化合物18n与 MCT4 胞质结构域的直接靶相互作用。体外用18n处理可抑制 MCT4 高表达细胞的乳酸外流并降低细胞活力。此外， 18n的药代动力学特性允许在小鼠肿瘤模型中评估乳酸调节和抗肿瘤活性。因此， 18n是研究选择性 MCT4 抑制及其对肿瘤生物学影响的宝贵工具。

  DOI：

  10.1021/acs.jmedchem.1c00448
• 作为产物：
  描述：

  2,3-二甲基苯甲醚 在 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 以96%的产率得到4-甲氧基-2,3-二甲基苯磺酰氯
  参考文献：
  名称：

  Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists

  摘要：

  The synthesis and preliminary structure-activity relationships (SAR) of a novel class of vasopressin V-1B receptor antagonists are described. Hit compound 5, identified via high throughput screening of the corporate collection, showed good activity in a V-1B binding assay (K-i 63 nM) but did not possess the lead-like physicochemical properties typically required in a hit compound. A 'deletion approach' on the HTS hit 5 was performed, with the focus on improvement of physicochemical properties, yielding the selective V-1B antagonist 9f (K-i 190 nM), with improved druglike characteristics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.104

文献信息

• Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors
  作者：Mauro Di Matteo、Alessandra Ammazzalorso、Federico Andreoli、Irene Caffa、Barbara De Filippis、Marialuigia Fantacuzzi、Letizia Giampietro、Cristina Maccallini、Alessio Nencioni、Marco Daniele Parenti、Debora Soncini、Alberto Del Rio、Rosa Amoroso

  DOI：10.1016/j.bmcl.2016.04.078

  日期：2016.7

  receptor positive breast cancer in post-menopausal women are aromatase inhibitors. In order to develop new aromatase inhibitors, we designed and synthesized new imidazolylmethylpiperidine sulfonamides using the structure of the previously identified aromatase inhibitor SYN 20028567 as starting lead. By this approach, three new aromatase inhibitors with IC50 values that are similar to that of letrozole and

  绝经后妇女最常使用的激素受体阳性乳腺癌治疗方法是芳香化酶抑制剂。为了开发新的芳香酶抑制剂，我们使用先前鉴定的芳香酶抑制剂SYN 20028567的结构作为起始铅，设计并合成了新的咪唑基甲基哌啶磺酰胺。通过这种方法，鉴定了三种新的芳香酶抑制剂，其IC50值与来曲唑和SYN 20028567相似。
• Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
  申请人：Barth Martine

  公开号：US20060178360A1

  公开（公告）日：2006-08-10

  The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy.

  本发明涉及新型苯磺酰胺化合物，由公式I和描述所定义，其制备方法及在治疗中的用途。
• Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
  申请人：Sabatucci Peter Joseph

  公开号：US20060160815A1

  公开（公告）日：2006-07-20

  This invention provides estrogen receptor modulators having the structure: wherein R 1 to R 7 , R 9 and R 10 X, Y, and Z are as defined in the specification; or a pharmaceutically acceptable salt thereof.

  该发明提供了具有以下结构的雌激素受体调节剂： 其中R1至R7、R9和R10、X、Y和Z如规范中所定义；或其药学上可接受的盐。
• 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
  申请人：Spinks Daniel

  公开号：US20050154023A1

  公开（公告）日：2005-07-14

  The present invention relates to 1-arylsulfonyl-3-substituted indole or indoline derivatives having the general formula I wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R 6 -R 11 , are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.

  本发明涉及具有一般式I的1-芳基磺酰基-3-取代吲哚或吲哚啉衍生物，其中虚线表示可选键；n为0或1；m为0-5，而Ar、R6-R11在说明中定义。本发明还涉及包含所述衍生物的制药组合物，并且涉及使用这些1-芳基磺酰基-3-取代吲哚或吲哚啉衍生物治疗中枢神经系统疾病，如精神病、精神分裂症、躁郁症、抑郁症、神经系统疾病、认知增强、帕金森病、肌萎缩性侧索硬化症、阿尔茨海默病和亨廷顿病。
• The discovery and SAR of indoline-3-carboxamides—A new series of 5-HT6 antagonists
  作者：Mark Reid、Ian Carlyle、Wilson L. Caulfield、Tom R. Clarkson、Fiona Cusick、Ola Epemolu、Robert Gilfillan、Richard Goodwin、David Jaap、Elise C. O’Donnell、Jeremy Presland、Zoran Rankovic、Daniel Spinks、Gayle Spinks、Anne M. Thomson、Fiona Thomson、James Strain、Grant Wishart

  DOI：10.1016/j.bmcl.2010.04.085

  日期：2010.6

  Antagonists of the 5-HT6 receptor have been shown to improve cognitive function in a wide range of animal models and as such may prove to be attractive agents for the symptomatic treatment of cognitive disorders such as Alzheimer's disease ( AD) and schizophrenia. We report herein the identification and SAR around N-(2-aminoalkyl)-1-(arylsulfonyl)indoline-3-carboxamides-a novel chemotype of 5-HT6 antagonists. (C) 2010 Elsevier Ltd. All rights reserved.